MNMD
|Mind Medicine Inc
NASDAQ
USD 7.30
-0.10|-1.35%
Current Price
USD 7.30
Change
USD -0.10 (-1.35%)
P/E Ratio
Dividend Yield
Market Cap
581.00M
Volume
830,632
Open
USD 7.34
Previous Close
USD 7.40
52-Week High
USD 10.44
52-Week Low
USD 4.70
About Mind Medicine Inc
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Robert Barrow
Employees:74
Headquarters:New York, USA
Website:www.mindmed.co
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions